The 20% You Give Up for Money You Could Borrow: The Series A Math Founders Skip

A 2026 Series A prices in a permanent claim on your upside. For a recurring-revenue company that already clears the revenue bar, that claim is a choice, not a requirement.

The median business-to-business SaaS Series A in 2026 clears at roughly a $12 million check on a $40 to $55 million pre-money valuation, and the founder gives up 18 to 22 percent of the company to close it. The same round requires $1.5 to $3 million in ARR before an investor will open a term sheet, which means every founder who qualifies to raise also qualifies, on revenue alone, to borrow. Most never run the second comparison.

The floor is set, and it is lower than founders remember

The Series A market corrected from its 2021 peak and has now held at that lower level for two years. For business-to-business SaaS, a $40 to $55 million pre-money valuation is not a soft opening bid that negotiation will lift by half. It is the market. AI-native companies command a two to three times premium on that number, but a recurring-revenue company without an AI-core product gets no such premium, and pricing a round as though 2021 multiples still apply is the fastest way to stall a raise for two quarters.

The dilution attached to that valuation is the part founders treat as fixed cost. Eighteen to 22 percent is not a rounding error on a cap table. It is a permanent claim on every dollar of enterprise value the company creates after the round, including the value the founder builds with the very capital being raised. That is the trade an equity round asks for: ownership now, in exchange for money that funds growth whose upside the new investor then shares.

The equity market has moved away from most software companies

The macro picture makes the trade worse, not better. Global startup funding reached a record $510 billion in the first half of 2026, but roughly 80 percent of second-quarter venture dollars went to AI-focused startups, and a majority of that went to a handful of the largest names. Underneath the record, North American seed funding fell about 27 percent in the same period. A founder reading "record funding year" and assuming an easy round is misreading the distribution. The capital is real, and it is concentrating somewhere a non-AI recurring-revenue company cannot follow.

That concentration changes the leverage in the room. A company raising into a thinner, more selective non-AI equity market takes the valuation and the dilution the market offers, not the ones the founder modeled. Negotiating from need, at a reset valuation, in a market pulling capital toward a different sector, is the weakest position from which to sell a fifth of a company.

The comparison that changes the decision

Here is the number most founders never put on the page. Twenty percent of a company that exits at $80 million is $16 million. Twenty percent of one that exits at $150 million is $30 million. That is the real, forward cost of a Series A's dilution, and it dwarfs the interest on a facility that could have funded the same growth plan. Debt has a coupon and a maturity. Equity has no maturity, and its cost compounds with every dollar of value the company goes on to create.

The reason the comparison gets skipped is that debt against recurring revenue was, for years, hard to find below the tier that required a recent equity round as a signal. That is no longer the constraint. Recurring revenue is a financeable asset on its own, and a company clearing the same $1.5 to $3 million ARR bar that qualifies it for a Series A has, in that revenue, the collateral a structured facility underwrites.

How Thalos Capital approaches this

Thalos Capital runs the debt-versus-dilution comparison before the first lender call, not after a term sheet is already on the table. The starting question is not "can this company raise" but "what is the cheapest capital that funds the plan," and for a recurring-revenue technology company with proven product-market fit and gross margin above 50 percent, the answer is frequently structured debt rather than sold equity.

Recurring Revenue Debt is built for exactly this profile. An Amortized Term Facility fits companies at $2 to $20 million in ARR, running three to six years with principal that ladders up as revenue grows. An Interest-Only Facility fits companies at $5 million or more in ARR, with interest-only payments and a balloon at term end. Both are structured around contracted recurring revenue rather than hard assets, and both carry no dilution, no board seats, and no warrants. The work is in matching the structure to the company's growth curve and cash profile, then to the source most likely to fund it on the best terms, so the founder funds the plan without giving up the upside that plan creates.

None of this argues that equity is always the wrong instrument. It argues that giving up a fifth of a company should be a decision made against a real alternative, not a default reached because the alternative was never priced.

A founder who takes the round without running the comparison does not learn what the dilution cost until the exit, when 20 percent of a larger number is the price of capital a facility could have carried for a fraction of it. Most financing situations have more options than the borrower initially sees. A conversation is enough to map them. Submit your financing request at https://thaloscapital.com/contact.